Want to take Stockholm3?
Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, a number of healthcare providers offer Stockholm3.
Participants in clinical studies
More cases of aggressive cancers found
Fewer unnecessary biopsies
Reduced healthcare costs
A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.
Stockholm3 study awarded as one of the best abstracts of the 2023 annual European Association of Urology meeting
March 20, 2023
New Stockholm3 data accepted for presentation at the upcoming European Association of Urology meeting
February 10, 2023
Groves Medical Group starts offering Stockholm3 in the UK
February 1, 2023